Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

2004P - Exome sequencing of germ-line DNA from young-onset and/or ALK-fusion-positive lung cancer patients

Date

17 Sep 2020

Session

E-Poster Display

Topics

Pathology/Molecular Biology

Tumour Site

Thoracic Malignancies

Presenters

Evgeny Imyanitov

Citation

Annals of Oncology (2020) 31 (suppl_4): S1052-S1064. 10.1016/annonc/annonc295

Authors

E. Imyanitov1, A. Sokolenko1, A. Iyevleva1, V. Tiurin1, T. Sokolova1, A.O. Ivantsov1, N. Mitiushkina1, S. Orlov2, E. Levchenko3, I. Bizin1

Author affiliations

  • 1 Department Of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 - Saint-Petersburg/RU
  • 2 Department Of Oncology, I.P. Pavlov Medical University, 197022 - Saint-Petersburg/RU
  • 3 Department Of Thoracic Oncology, N.N. Petrov Institute of Oncology, 197758 - Saint-Petersburg/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2004P

Background

A small subset of lung carcinomas (LCs) occur in non-smokers, with some patients developing the malignancy in an unusually young age. This mode of disease appearance is particularly characteristic for ALK-driven LCs. We hypothesized that young-onset and/or ALK-fusion-positive LC may be associated with a germ-line genetic defect. We expected that if a potential causative allele will be detected, its significance could be validated in an extended genotyping study due to existence of founder effect in Russian population.

Methods

The study included 19 LC patients [14 fusion-positive LCs (age range: 24-71 years; 6/14 (43%) subjects aged < 45 years); 3 young-onset (< 40 years) LCs with negative or unknown fusion status; 2 women with multiple primary tumors (bilateral LC, 47 years and LC + cervical cancer, 43 years)]. Blood DNA was subjected to exome sequencing. Data analysis considered truncating heterozygous mutations and potentially pathogenic biallelic missense mutations in genes with known role in cancer pathogenesis.

Results

There were single instances of ATM p. Q1478X, BARD1 c. 2300_2301del, CHEK2 c.1046dupA, XPA c.268_269insA and XRCC2 c.96delT heterozygous mutations. The analysis of consecutive LC cases (n = 420-456), ALK-fusion positive LCs (n = 95-166) and young-onset LC patients (n = 80-173) did not reveal additional instances of these alleles. In addition, we considered for further study biallelic c.C883T (p.T278I) mutation in the NEIL1 gene, which was detected in one patient and was very likely to affect the function of the protein. Case-control study involving 554 LC patients and 250 healthy controls revealed equal frequency (3.2%) of NEIL1 c.C883T heterozygotes in both groups, while no new instances of homozygous genotype was identified.

Conclusions

Although young-onset and/or ALK-fusion-positive LCs constitute an especial category of LC, this exome sequencing study failed to identify germ-line predisposing factors for this disease.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This study has been supported by the Russian Science Foundation.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.